Evelo Biosciences, Inc.
DelistedCIK 1694665fmd_06R2NF01HGHNHGYA2ARE2HMZ24Manufacturing · Pharmaceutical PreparationsTemplate: Standard
Coverage: Jan 01, 2016 to Sep 30, 2023, 28 periods
| Line item | FY2016 | FY2017 | FY2018 | FY2019 | FY2020 | FY2021 | FY2022 |
|---|---|---|---|---|---|---|---|
| Research and development | 9 | 20 | 40 | 63 | 70 | 84 | 79 |
| Total operating expenses | 13 | 28 | 58 | 86 | 92 | 115 | 108 |
| Operating income | (13) | (28) | (58) | (86) | (92) | (115) | (108) |
| Interest expense | 0 | 1 | 1 | – | – | – | – |
| Other non-operating income (expense) | (0) | (1) | 1 | 1 | (1) | (6) | (5) |
| Income before taxes | – | (28) | (57) | (85) | (93) | (122) | (114) |
| Income tax expense | – | 0 | 0 | 0 | 0 | 0 | 1 |
| Net income from continuing operations | – | (28) | (57) | (85) | (94) | (122) | (115) |
| Net income | (13) | (28) | (57) | (85) | (94) | (122) | (115) |
| Net income to common shareholders | (15) | (34) | (61) | (85) | – | – | – |